We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$364M
AUM Growth
-$61.7M
Cap. Flow
-$51.8M
Cap. Flow %
-14.24%
Top 10 Hldgs %
49.17%
Holding
67
New
17
Increased
9
Reduced
10
Closed
14

Top Buys

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$13.3M
2
ALLO icon
Allogene Therapeutics
ALLO
+$7.84M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$5.72M
4
TARS icon
Tarsus Pharmaceuticals
TARS
+$5.31M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$4.28M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$9.65M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$8.69M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$7.95M
4
IWM icon
iShares Russell 2000 ETF
IWM
+$6.63M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$6.59M

Sector Composition

Rank Sector Weight
1 Healthcare 84.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
26
MoonLake Immunotherapeutics
MLTX
$1.59B
$5.17M 1.42%
500,000
– –
LKFT
27
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.94B
$5.17M 1.42%
+75,000
New +$5.72M
TARS icon
28
Tarsus Pharmaceuticals
TARS
$2.52B
$4.93M 1.35%
+170,000
New +$5.31M
CRNX icon
29
Crinetics Pharmaceuticals
CRNX
$8.88B
$4.59M 1.26%
+243,309
New +$4.28M
ISEE
30
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.58M 1.26%
725,000
-400,000
-36% -$2.58M
ACRS icon
31
Aclaris Therapeutics
ACRS
$749M
$4.39M 1.21%
250,000
-350,000
-58% -$7.95M
GYRE icon
32
Gyre Therapeutics
GYRE
$716M
$4.33M 1.19%
133,333
– –
CTIC
33
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$4M 1.1%
1,600,000
+850,000
+113% +$2.04M
SRRA
34
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.89M 1.07%
200,000
– –
HRMY icon
35
Harmony Biosciences
HRMY
$1.94B
$3.53M 0.97%
+125,000
New +$3.75M
PCVX icon
36
Vaxcyte
PCVX
$8.09B
$3.26M 0.9%
+145,000
New +$2.97M
IMUX icon
37
Immunic
IMUX
$205M
$3.25M 0.89%
26,500
– –
KDMN
38
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.1M 0.85%
800,000
+200,000
+33% +$775K
FOLD
39
DELISTED
Amicus Therapeutics
FOLD
$2.56M 0.7%
265,000
– –
IMVT icon
40
CALL
Immunovant
IMVT
$8B
$2.11M 0.58%
+200,000
New +$2.79M
CRIS icon
41
Curis
CRIS
$9.71M
$1.99M 0.55%
618
-445
-42% -$2.01M
CERE
42
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$1.92M 0.53%
+75,000
New +$1.07M
CMRX
43
DELISTED
Chimerix, Inc.
CMRX
$1.6M 0.44%
200,000
– –
MRUS
44
DELISTED
Merus
MRUS
$1.58M 0.43%
+75,000
New +$1.66M
ELEV
45
DELISTED
Elevation Oncology
ELEV
$1.36M 0.37%
+100,000
New +$1.24M
PRVB
46
PUT
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$1.26M 0.35%
+150,000
New +$1.21M
CASI
47
DELISTED
CASI Pharmaceuticals
CASI
$1.01M 0.28%
65,000
– –
OTIC
48
DELISTED
Otonomy, Inc.
OTIC
$1M 0.28%
450,000
– –
LRMR icon
49
Larimar Therapeutics
LRMR
$381M
$982K 0.27%
+100,000
New +$1.13M
MRNA icon
50
Moderna
MRNA
$25.1B
$940K 0.26%
+4,000
New +$715K
1
2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Ghost Tree Capital held 67 positions worth $364M, down 14% from $425M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Ghost Tree Capital withdrew a net $51.8M in Q2 2021, closing 14 positions and reducing 10 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $9.65M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 77% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in RAPT Therapeutics worth $18.1M.

  • Ghost Tree Capital's largest Q2 2021 buy was RAPT Therapeutics: 71,250 shares worth $18.1M.
  • Ghost Tree Capital added most to Biogen in Q2 2021, an estimated $3.79M increase.
  • Ghost Tree Capital's biggest Q2 2021 reduction was Rocket Pharmaceuticals, cutting an estimated $8.69M.
  • Ghost Tree Capital fully exited Apellis Pharmaceuticals in Q2 2021, selling an estimated $9.65M.
  • Ghost Tree Capital's ten largest holdings make up 49% of its $364M portfolio in Q2 2021.
  • Ghost Tree Capital opened 17 new positions and closed 14 in Q2 2021.
  • Ghost Tree Capital's portfolio value fell 14% quarter-over-quarter to $364M.

Based on Ghost Tree Capital's 13F filing for Q2 2021, filed 11 Aug 2021.